Press

HAVN Life Acquires Bennett’s Choice Patented Brain Health and Recovery Formulations

Sep 29 • 4 min read

Quick Take: The Acquisition will add more products to HAVN Life’s existing line of natural health products, with additional product launches planned in the near future. Havn Life Sciences Inc. (CSE: HAVN) (OTC: HAVLF), a biotechnology company developing natural health products and innovative therapies to support brain health and enhance the capabilities of the mind is pleased…

BetterLife Pharma Enrolls First Patient in Interferon alpha-2b COVID-19 Trial in Chile

Sep 28 • 5 min read

Quick Take: BetterLife, an emerging biotechnology company with focuses on psychedelics and delivery technology, has enrolled the first patient in their COVID-19 alpha-2b trial. The trial will take place through BetterLife’s wholly owned subsidiary, Altum Pharmaceuticals. BetterLife Pharma Inc. (CSE: BETR / OTCQB: BETRF) today announced that its wholly owned subsidiary, Altum Pharmaceuticals Inc. (“Altum”), and Pontificia Universidad Católica de Chile have enrolled…

MINDCURE Launches “Desire Project” To Treat Female Hypoactive Sexual Desire Disorder With MDMA-Assisted Psychotherapy

Sep 27 • 4 min read

Quick Take: The research will mark the first psychedelic treatment program for Hypoactive Sexual Desire Disorder (HSDD). Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF), a leader in advanced proprietary technology and research in psychedelics, introduces its “Desire Project,” a clinical research program focused on the treatment of female hypoactive sexual desire disorder with MDMA-assisted psychotherapy. …

Delix Therapeutics Closes $70 Million Series A Financing to Advance Pipeline of Novel Psychoplastogen Therapeutics to Treat Brain Disorders

Sep 27 • 4 min read

Quick Take: The round was led by ARTIS Ventures, RA Capital Management, and OMX Ventures. The proceeds will advance two of their leading psychedelic candidates. Preclinical neuroscience company Delix Therapeutics (the “Company”), today announced the closing of a $70 million Series A financing round. The round was led by ARTIS Ventures, RA Capital Management, and…

MindMed and Liechti Lab Provide Results from their Psilocybin R&D Collaboration

Sep 24 • 3 min read

Quick Take: The findings include psilocybin interactions with SSRIs and LSD vs. psilocybin dosages in a clinical setting. Mind Medicine Inc. (NASDAQ: MNMD), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce that Dr. Matthias Liechti presented data from several ongoing studies at the INSIGHT Conference in Berlin, Germany. These investigator-initiated studies are being conducted as part of MindMed’s…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441